Houston named a top 10 big city for ethnic diversity by new study

BAYOU CITY BRAGGING RIGHTS

A new study ranks Houston as the country's 10th most ethnically diverse large city. Getty Images

Houston prides itself on its diversity — and rightfully so. A new study ranks Houston as the country's 10th most ethnically diverse large city.

Among 501 U.S. cities, Houston also ranks 28th overall and first in Texas, according to the study, released February 11 by personal finance website WalletHub.

To come up its ranking, WalletHub measured three key indicators of ethnic diversity: language, ethnicity and race, and birthplace. Houston ranks 25th for language diversity, 36th for ethnic and racial diversity, and 244th for birthplace diversity.

This finding differs from a study by Rice University's Kinder Institute for Urban Research that found Houston was the most ethnically and racially diverse metro area in the U.S. as of 2010. Why the disparity? The WalletHub study looked at data for the city of Houston, while the Kinder Institute study examined data for the entire Houston metro area.

The new finding also differs from a broader WalletHub study published in April 2019. In that study, Houston was crowned the most diverse city in the U.S., based on socioeconomic, cultural, economic, household, and religious diversity. Ethnic diversity is only one component of that ranking.

"Houston is the most diverse city in the United States. But diversity alone is not enough — we must always strive to be more inclusive," Houston Mayor Sylvester Turner tweeted in December 2019. "As your mayor, I know that diversity and inclusivity are what makes us strong. And I will always work to build one complete Houston."

However you slice it, Houston leads the pack in Texas for ethnic and racial diversity. Here's how other major cities in the Lone Star State fare in the new WalletHub study:

  • Arlington, No. 38
  • Plano, No. 46
  • Dallas, No. 47
  • Fort Worth, No. 62
  • Austin, No. 73
  • San Antonio, No. 136

While Austin and cities in the Dallas-Fort Worth area don't rank particularly high in the WalletHub study, Austin and DFW do show up on a recent list of the country's most racially diverse metro areas.

DFW held the No. 11 spot in the Bloomberg news service's 2018 ranking of racial diversity among the 100 largest U.S. metros, while Austin stood at No. 19. Houston bested both of those areas, though, landing at No. 5.

Austin and Dallas didn't perform as well in a racial and ethnic index compiled by U.S. News & World Report.

The index shows the racial and ethnic diversity of Dallas actually slipped 3.4 percent from 2010 to 2018, with Austin's diversity declining by 0.10 percent. The decrease was 2.6 percent in San Antonio and 1.2 percent in Houston, the index shows.

The diversity picture was brighter in other Texas cities included in the U.S. New & World Report index, which measured racial and ethnic diversity in U.S. cities with at least 300,000 residents. Arlington saw its racial and ethnic diversity rise 3.6 percent from 2010 to 2018, with Fort Worth at 1.8 percent.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”